Table 3.
Management of patients with COVID-19
| Characteristic | All (N=64) | Severe group (n=44) | Critical group (n=20) | P value |
|---|---|---|---|---|
| Hydroxychloroquine | 52 (81) | 33 (75) | 19 (95) | .06 |
| Antibiotic treatment for CAP | 36 (56) | 22 (50) | 14 (70) | .14 |
| Remdesivir | 16 (25) | 3 (7) | 13 (65) | <.001 |
| Convalescent serum | 1 (2) | 0 (0) | 1 (5) | .31 |
| Steroids for maternal treatment | 15 (23) | 4 (9) | 11 (55) | <.001 |
| Anticoagulants during admission | ||||
| Prophylactic heparin/LMWH | 37 (58) | 25 (57) | 12 (60) | .81 |
| Therapeutic heparin/LMWH | 10 (16) | 2 (5) | 8 (40) | <.001 |
| Supplemental O2 | 52 (81) | 32 (73) | 20 (100) | .01 |
| High-flow nasal cannula | 16 (25) | 5 (11) | 11 (55) | <.0001 |
| BiPAP/CPAP | 5 (8) | 1 (2) | 4 (20) | .03 |
| Intubated | 19 (30) | 0 (0) | 19 (95) | <.001 |
| Reintubated | 4 (6) | 0 (0) | 4 (20) | .008 |
| Prone positioning | 4 (6) | 0 (0) | 4 (20) | .008 |
| ECMO | 0 (0) | 0 (0) | 0 (0) | 1.00 |
| ARDS | 14 (22) | 0 (0) | 14 (70) | <.001 |
| New-onset maternal cardiomyopathy | 0 (0) | 0 (0) | 0 (0) | 1.00 |
| Maternal cardiac arrest | 1 (2) | 0 (0) | 1 (5) | <.001 |
| Maternal mortality | 0 (0) | 0 (0) | 0 (0) | 1.00 |
Data are presented as n (%).
ARDS, acute respiratory distress syndrome; BiPAP, bilevel positive airway pressure; CAP, community-acquired pneumonia; COVID-19, coronavirus disease 2019; CPAP, continuous positive airway pressure; ECMO, extracorporeal membrane oxygenation; LMWH, low-molecular-weight heparin.
Pierce-Williams et al. Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies. AJOG MFM 2020.